Galanis E, et al. - In preclinical models, effective blocking of bevacizumab-induced glioma invasion by dasatinib (Src family kinase inhibitor) led researchers to investigate whether an increased bevacizumab efficacy in patients with recurrent glioblastoma (GBM) could be achieved by combining bevacizumab with dasatinib. Either 100 mg of oral dasatinib twice daily (arm A) or placebo (arm B) was randomly 2:1 received by patients with recurrent GBM on days 1 to 14 of each 14-day cycle combined with 10 mg/kg of intravenous bevacizumab on day 1 of each 14-day cycle in phase 2 trial following the completion of the phase 1 component. Six-month progression-free survival (PFS6) was the primary endpoint. Evaluable patients were 121. In these patients, numerically but not statistically higher PFS6 rate was found in arm A vs arm B. Despite upregulation of Src signaling in GBM patients, no significant improvement in the outcomes of patients with recurrent GBM was observed with the combination of bevacizumab with dasatinib vs bevacizumab alone.